Sign in
Taking people in United StatesNo phase

Studies older adults with advanced bladder cancer who cannot receive cisplatin

Looks at how a geriatric survey predicts outcomes in older adults with advanced bladder cancer.

Key facts

Who runs it
Dana-Farber Cancer Institute
Where
Boston, United StatesSee the site
Trial code
Registry title
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Status
Recruiting
People taking part
180 people, planned
Started
5 Mar 2024
Expected to end
1 Jan 2028
Type of study
Observational
Treatments tested
  • Geriatric-8 Survey
  • National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
  • Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Record updated
17 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 65 or older with advanced or metastatic bladder cancer (urothelial carcinoma) who cannot have cisplatin chemotherapy and are getting treatment.

Age
65 years or older. Only 20% of all participants may be aged 65-70.
Sex
All sexes can join.
Disease stage
Bladder cancer that cannot be removed by surgery or has spread, proven to be urothelial carcinoma. Variant histology is allowed.
Earlier treatment
The primary oncologist must judge the person cannot have cisplatin. The person is getting chemotherapy (with or without immunotherapy maintenance), enfortumab vedotin-pembrolizumab, or immunotherapy alone.

Main reasons for not taking part

  • Chooses not to have cancer treatment
  • Gets care outside DFCI or DFCI affiliate sites
  • Advanced cognitive impairment or cannot complete surveys
  • Is receiving other investigational agents for this condition

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population)
  • Unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma. Any component of variant histology is allowed
  • Cisplatin-ineligible as determined by the subject's primary oncologist
  • Receiving treatment with chemotherapy (+/- immunotherapy maintenance), enfortumab vedotin-pembrolizumab combination therapy or immunotherapy alone
  • Ability to understand and the willingness to sign a written informed consent document and to complete patient reported outcomes that will be in English or Spanish either alone or with assistance of study researcher or family

Who cannot take part

  • Participants who are receiving any other investigational agents for this condition (if appropriate only)
  • Subjects who elect to not undergo cancer-directed therapy
  • Advanced cognitive impairment or inability to complete surveys
  • Subjects obtaining their care outside of DFCI or DFCI affiliate sites

Where in United States

  • Dana-Farber Cancer InstituteBoston, United StatesContact: Joaquim Bellmunt, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.

The group in the trial

  • Cisplatin-Ineligible Metastatic Bladder Cancer

    Participants receiving standard of care non-cisplatin based therapy (carboplatin-based chemotherapy, enfortumab vedotin plus pembrolizumab or immunotherapy) and will complete study procedures as outlined below: * Baseline visit with questionnaires. * Complete surveys every 3 weeks by telephone or by in-office visit for 8 months. * Optional follow-up phone calls every 6 months for up to 3 years.

    Treatment: Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Plain-language title
Studies older adults with advanced bladder cancer who cannot receive cisplatinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 February 2026